Anti-Motion Sickness Medications in Dyslexia

  • Harold N. Levinson


The experimental attempt to treat dyslexic individuals with anti-motion sickness medications was based on the following reasoning: (1) If, indeed, the sensory-motor dysmetria underlying dyslexia is of a primary c-v origin; and (2) if the cerebellum modulates the motion input in a manner analogous to its demonstrated role in modulating the visual, acoustic, proprioceptive and tactile input; and (3) if the anti-motion sickness medications improve the functional capacity of the cerebellum (and vestibular circuits) to process and modulate motion input and autonomic motion-sickness reflexes; then perhaps these very same “motion” medications may similarly improve the cerebellum’s capacity to modulate and harmonize the non-motion sensory-motor organismic dysmetria characterizing and underlying dyslexia. Furthermore, if these hypotheses are correct, any and all pharmacologically induced therapeutic responses in dyslexia may be viewed as neurophysiologic indicators suggesting that subclinically impaired c-v functional patterns were being compensated for by chemically improved c-v modulating and sensory-motor processing capacity. In addition, the chemically triggered and clinically observed conversion of “dyslexic” to improved or “normal” functioning may be utilized to highlight, and thus explore, the specific c-v neurodynamic role in dyslexic functioning, and to test the c-v potency of specific chemical agents.


Therapeutic Response Placebo Effect Motion Sickness Favorable Response Dyslexic Child 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag New York Inc. 1980

Authors and Affiliations

  • Harold N. Levinson
    • 1
  1. 1.New York University Medical CenterNew YorkUSA

Personalised recommendations